<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943576</url>
  </required_header>
  <id_info>
    <org_study_id>GXCPC1</org_study_id>
    <nct_id>NCT03943576</nct_id>
  </id_info>
  <brief_title>Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis</brief_title>
  <official_title>Adipose-Derived Stem Cells (ADSCs) Injections for Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gwo Xi Stem Cell Applied Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gwo Xi Stem Cell Applied Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the investigators study was to investigate the safety and efficacy of allogeneic&#xD;
      ADSCs for the clinical treatment of knee osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC pain score</measure>
    <time_frame>week 24</time_frame>
    <description>Change from baseline in WOMAC pain score at Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI</measure>
    <time_frame>week 0, 24, 48</time_frame>
    <description>Change from baseline to post-treatment visits on the target knee in MRI examination results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>week 0, 1, 4, 12, 24</time_frame>
    <description>Changes from baseline to post-treatment visits on the target knee in Visual Analogue Scale (VAS) for pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-item Short Form (SF-12)</measure>
    <time_frame>week 0, 1, 4, 12, 24</time_frame>
    <description>Change from baseline to post-treatment visits in total score of 12-item Short Form (SF-12) health survey questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>GXCPC1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GXCPC1 contains 6.7×10^6 or 4×10^7 allogeneic adipose-derived stem cells (ADSCs) in 3 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hyaluronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hya Joint Plus synovial fluid supplement 3mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GXCPC1</intervention_name>
    <description>The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10^6 or 4×10^7 ADSCs in 3 mL saline. (allogeneic injection)</description>
    <arm_group_label>GXCPC1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HA</intervention_name>
    <description>Hya Joint Plus synovial fluid supplement 3mL</description>
    <arm_group_label>hyaluronic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Aged 40 to 80 years old (inclusive)&#xD;
&#xD;
          3. Kellgren-Lawrence grading II-IV, as determined by American College ofRheumatology&#xD;
             (ACR) criteria for osteoarthritis of the knee&#xD;
&#xD;
          4. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score of 7&#xD;
             ~ 17 (inclusive) in the target knee despite use of NSAID&#xD;
&#xD;
          5. Contraindicated to long term systemic NSAID (e.g. suffer from severe gastrointestinal&#xD;
             side effects upon systemic NSAID administration, or due to underlying increased&#xD;
             gastrointestinal, cardiovascular, or renal risk) and not able to receive or wish to&#xD;
             delay knee arthroplasty&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With previous surgery of articular fracture, ligament reconstruction, meniscal&#xD;
             reconstruction, and knee arthroplasty on the target knee joint&#xD;
&#xD;
          2. With previous intra-articular intervention (e.g. steroid, anesthetics, hyaluronate,&#xD;
             arthroscopic surgery) on the target knee joint 12 weeks prior to screening&#xD;
&#xD;
          3. Administered or required systemic or local on the target knee joint immunosuppressive&#xD;
             agent, anti-inflammatory drug, steroid, analgesics, opioid, or duloxetine for OA knee&#xD;
             except for acetaminophen and NSAID within 1 week prior to screening&#xD;
&#xD;
          4. With joint diseases other than knee osteoarthritis considered by investigator not&#xD;
             eligible to enter the study&#xD;
&#xD;
          5. Unable to receive MRI examination, including allergic to the contrast medium for MRI&#xD;
             used in the study, with known history of claustrophobia, having any existing metallic&#xD;
             intraocular foreign body or active/inactive implanted medical devices, such as cardiac&#xD;
             pacemaker, cochlear, intracranial vascular clips or neurostimulator&#xD;
&#xD;
          6. Active or suspected infection of the target knee joint&#xD;
&#xD;
          7. History of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          8. History of malignancy within 2 years prior to screening&#xD;
&#xD;
          9. With body mass index (BMI) greater or equal to 35 kg/m2&#xD;
&#xD;
         10. Known hypersensitivity to any component of the investigational product or the active&#xD;
             control&#xD;
&#xD;
         11. Participated other investigational study within 4 weeks prior to screening&#xD;
&#xD;
         12. With ongoing or within the past 2 years serious medical conditions (e.g. concomitant&#xD;
             illness) such as cardiovascular (e.g. New York Heart Association grade III or IV),&#xD;
             hepatic (e.g. Child-Pugh Class C), psychiatric condition (e.g. alcoholism, drug&#xD;
             abuse), medical history, physical findings, or laboratory abnormality that in the&#xD;
             investigators' opinion could interfere with the results of the trial or adversely&#xD;
             affect the safety of the subject&#xD;
&#xD;
         13. Female subject with childbearing potential who is lactating or has positive serum or&#xD;
             urine pregnancy test at Screening&#xD;
&#xD;
         14. Subject with childbearing potential refuses to use highly effective contraceptives&#xD;
             from signing informed consent until Final/Early Termination Visit. At least two forms&#xD;
             of birth control must be adopted and one of which must be a barrier method. Acceptable&#xD;
             forms include:&#xD;
&#xD;
               -  Established use of oral, injected or implanted hormonal methods of contraception&#xD;
&#xD;
               -  Placement of an intrauterine device (IUD) or intrauterine system (IUS)&#xD;
&#xD;
               -  Barrier methods of contraception: condom, or occlusive cap (diaphragmor&#xD;
                  cervical/vault caps)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng-FONG Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chia-Hsin Lee</last_name>
    <phone>+886 6585959</phone>
    <phone_ext>341</phone_ext>
    <email>jessie.lee@gwoxi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GWOXI Stem Cell Applied Technology Co., Ltd.</name>
      <address>
        <city>Hsinchu</city>
        <zip>30261</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia-Hsin Lee</last_name>
      <phone>+886 6585959</phone>
      <phone_ext>341</phone_ext>
      <email>jessie.lee@gwoxi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

